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This study aimed to evaluate the immunoexpression of glucose transporters 1 (GLUT-1) 
and 3 (GLUT-3) in metastatic and non-metastatic lower lip squamous cell carcinoma 
(LLSCC). Twenty LLSCCs with regional nodal metastasis and 20 LLSCCs without metastasis 
were selected. The distribution of staining and the percentage of GLUT-1 and GLUT-3 
staining in each tumor core and at the deep invasive front were assessed. Most tumors 
(70%) exhibited peripheral staining for GLUT-1 in nests, sheets and islands of neoplastic 
cells, whereas predominantly central staining was observed for GLUT-3 (72.5%). A high 
percentage of GLUT-1-positive cells was observed at the deep invasive front and in the 
tumor core of metastatic and non-metastatic tumors (p>0.05). The percentage of GLUT-1-
positive cells was much higher than that of GLUT-3-positive cells both in the deep invasive 
front (p<0.001) and in the tumor core (p<0.001) of LLSCCs. No significant differences in 
the percentage of GLUT-1- and GLUT-3-positive cells were observed according to nodal 
metastasis, clinical stage or histological grade of malignancy (p>0.05). In conclusion, the 
results of the present study suggest an important role of GLUT-1 in glucose uptake in 
LLSCCs, although this protein does not seem to be involved in the progression of these 
tumors. On the other hand, GLUT-3 expression may represent a secondary glucose uptake 
mechanism in LLSCCs.
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Introduction
Squamous cell carcinoma is the most common 
malignancy in the lower lip (1). Although lower lip 
squamous cell carcinoma (LLSCC) is slow growing, up to 
29% of tumors develop metastases to the cervical lymph 
nodes (2). Patients who develop late cervical metastases 
have a poor prognosis, with a 5-year survival rate of only 
25% to 50% (3).
Biologically, growing malignant tumors require the 
formation of blood vessels to increase respiration rates and 
nutrient absorption (4). However, angiogenesis does not 
accompany the growth of neoplastic cells, a fact resulting 
in areas of hypoxia in the tumor (5,6). The neoplastic cells 
then undergo changes in order to adapt to and survive 
under these conditions, favoring invasion and metastases. 
During this process of adaptation, malignant neoplastic 
cells increase the uptake and metabolism of glucose (5,7,8).
The regulation of the expression of glucose transporter 
proteins plays a critical role in the supply of glucose and 
other hexoses to metabolically active cells (7). Important 
proteins of this group are glucose transporters 1 (GLUT-1) 
and 3 (GLUT-3). Overexpression of these two proteins has 
been demonstrated in different malignant tumors such 
as esophageal, breast, and ovarian carcinomas (7,9). In 
most of these cancers, elevated expression levels of these 
proteins have been associated with unfavorable clinical 
outcomes (7,9). The few studies on oral squamous cell 
carcinomas (OSCCs) have shown an association between 
the overexpression of GLUT-1 and the presence of lymph 
node metastases (10–12), episodes of recurrence (10,13), 
and low patient survival (4,13,14). With respect to GLUT-3, 
Ayala et al. (15) found that the expression of this protein 
was associated with an advanced clinical stage of OSCC 
and lower disease-free survival rates.
Despite the large number of studies investigating 
the role of GLUTs in the development and progression of 
different human cancers, a search of the Pubmed database 
identified no reports on the expression of GLUT-1 and -3 in 
LLSCC. Therefore, the objective of the present study was to 
evaluate the immunoexpression of GLUT-1 and GLUT-3 in 
metastatic and non-metastatic LLSCCs and its association 
with TNM stage and histological grade of malignancy.
Material and Methods
Forty cases of LLSCC, obtained from the files of Dr. 
Luiz Antônio Hospital, Natal, RN, Brazil, were selected for 
this study. The specimens were divided into two groups: 
a non-metastatic group consisting of 20 cases of LLSCC 
without regional lymph node metastasis, and a metastatic 
group consisting of 20 cases of LLSCC with regional lymph 
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node metastasis. Information regarding the presence or 
absence of regional lymph node metastasis and clinical 
staging (TNM) was collected from the patient records. The 
study was approved by the Research Ethics Committee of 
Dr. Luiz Antônio Hospital, Natal, RN, Brazil.
Sections (5 µm) were cut from paraffin-embedded tissue 
blocks, deparaffinized, and stained with hematoxylin and 
eosin for histological examination. The histological grade 
of malignancy was established for each case of LLSCC in a 
blind fashion by two observers. The tumors were graded as 
well-differentiated, moderately differentiated, and poorly 
differentiated according to World Health Organization 
(WHO) criteria (16).
In addition, the histological grade of malignancy at 
the tumor-host interface was established using the system 
proposed by Bryne (17), in which scores are attributed to 
the following parameters: degree of keratinization, nuclear 
pleomorphism, pattern of invasion, and inflammatory 
infiltrate. These scores are summed to provide a total 
malignancy score. Cases with a total score ≤8 were classified 
as low-grade malignancy and those with a total score >8 
were classified as high-grade malignancy according to the 
method adopted by Silveira et al. (18).
Immunohistochemistry
For immunohistochemical study, 3-µm-thick sections 
were cut from paraffin-embedded tissue blocks. The 
sections were deparaffinized and immersed in 3% hydrogen 
peroxide to block endogenous peroxidase activity. Next, 
the sections were washed in phosphate-buffered saline 
(PBS). The antigen retrieval procedure, antibody dilution, 
and clone type for GLUT-1 and -3 are shown in Table 1. 
After treatment with normal serum, the sections were 
incubated with the primary antibodies in a moist chamber. 
The tissue sections were then washed twice in PBS and 
treated with a polymer-based complex (AdvanceTM HRP; 
Dako, Carpinteria, CA, USA) at room temperature to bind 
the primary antibodies. Peroxidase activity was visualized by 
immersing the sections in diaminobenzidine (Liquid DAB+ 
Substrate, Dako), resulting in a brown reaction product. 
Finally, the sections were counterstained with Mayer 
hematoxylin and coverslipped. Erythrocytes present in each 
section served as internal positive control for anti-GLUT-1 
antibody, and inflammatory cells of the adjacent tumor 
were used as internal positive control for anti-GLUT-3 
antibody. As negative control, the samples were treated 
as described above, except that the primary antibody was 
replaced with a solution of bovine serum albumin in PBS.
Analysis of Immunostaining
Immunohistochemical analysis was performed by 
two observers in a blind fashion by two observers under 
an Olympus CX41 light microscope (Olympus Co., Tokyo, 
Japan). Expression of GLUT-1 and GLUT-3 was analyzed 
only in neoplastic epithelial cells.
The immunoexpression of GLUT-1 and -3 was evaluated 
quantitatively using an adaptation of the method proposed 
by Ohba et al. (8). Five fields in the tumor core and at the 
deep invasive front that contained the largest number of 
immunostained cells were identified by light microscopy. 
Digital images of these five microscopic fields (×200 
magnification) were acquired with an Olympus EVOLT 
E-330 digital camera (Olympus Co.) and transferred to the 
Image J® software (National Institute of Mental Health, 
Bethesda, MD, USA). The number of positive and negative 
cells was determined in each field and the percentage of 
cells exhibiting cytoplasmic and/or membrane staining for 
GLUT-1 and GLUT-3 was calculated for each case.
The pattern of GLUT-1 and GLUT-3 staining was 
evaluated throughout the tumor at magnifications of 40× 
and 200×. The cases were assigned to one of the following 
groups based on the predominant pattern of staining in 
nests, sheets and islands of neoplastic cells: predominantly 
central staining, predominantly peripheral staining, and 
similar staining in central and peripheral areas.
Statistical Analysis
The results were analyzed statistically using the 
Statistical Package for the Social Sciences (version 17.0; 
SPSS Inc., Chicago, IL, USA). For clinical staging, stages I 
and II were combined into one group and stages III and IV 
into another group. Similarly, for histological grading of 
malignancy, moderately and poorly differentiated tumors 
were combined into one group and compared to well-
differentiated tumors. The percentage of GLUT-1- and 
GLUT-3-immunopositive cells in the tumor core and at 
the tumor front was compared by the non-parametric 
Mann-Whitney test and the Wilcoxon signed rank test. 
Spearman’s correlation test was used to determine possible 
correlations between the percentages of GLUT-1- and 
Table 1. Catalog number, specificity, company, dilution, antigen retrieval and incubation of the primary antibodies
Catalog number Specificity Company Dilution Antigen retrieval Incubation
GTX15309 GLUT-1 GeneTex Inc., San Antonio, TX, USA 1:400 Citrate, pH 6.0 Pascal, 121°C, 3 min 60 min
GTX15311 GLUT-3 GeneTex Inc., San Antonio, TX, USA 1:400 Citrate, pH 6.0 Pascal, 121°C, 3 min 60 min











GLUT-3-immunopositive cells. A level of significance of 
5% (p<0.05) was adopted for all tests.
Results
Clinical and Morphological Analysis
Regarding clinical stage, five (12.5%) cases were 
classified as stage I, 13 (32.5%) as stage II, 11 (27.5%) as 
stage III, and 11 (27.5%) as stage IV. Histological grading 
of malignancy proposed by the WHO classified 12 (30%) 
cases as well-differentiated, 21 (52.5%) as moderately 
differentiated, and 7 (17.5%) as poorly differentiated. 
Twenty-two (55%) cases were classified as low-grade 
malignancy at the tumor invasive front and 18 cases (45%) 
as high-grade malignancy.
Most metastatic LLSCCs were classified as high-grade 
malignancy (70%) or moderately/poorly differentiated 
tumors (90%) (p=0.004 and p=0.014, respectively). Most 
patients in stages III and IV (63.6%) had high-grade 
malignancy tumors (p=0.012). Similarly, most moderately/
poorly differentiated tumors (64.3%) were observed in 
patients in stages III and IV (p=0.093). Median percentages 
of positivity for GLUT-1 and GLUT-3 are summarized in 
Table 2.
Analysis of Immunostaining
All cases of LLSCC were positive for GLUT-1 and GLUT-3. 
With respect to the pattern of staining, most tumors (70%) 
exhibited a predominantly peripheral staining for GLUT-
1 in nests, sheets and islands of neoplastic cells. Strong 
GLUT-1 immunostaining was especially evident in areas 
of necrosis. In central areas of the tumor islands, GLUT-1 
immunoexpression was mainly weak or absent, particularly 
in keratinization foci. In contrast, staining for GLUT-3 
was predominantly central in nests, sheets and islands of 
neoplastic cells in most LLSCCs (72.5%).
A high percentage of cytoplasmic and/or membrane 
staining for GLUT-1 was observed at the deep invasive 
front (Fig. 1A) and in the tumor core (Fig. 1B) of 
metastatic and non-metastatic tumors. However, 
the non-parametric Mann-Whitney test revealed 
no statistically significant difference between 
groups (Table 2). In all tumors, the percentage of 
GLUT-3-positive cells was much lower than that of 
GLUT-1-positive cells. In addition, the percentage of 
cytoplasmic and/or membrane staining for GLUT-3 
at the deep invasive front was similar in metastatic 
and non-metastatic tumors (Fig. 1C) (p=0.482) 
(Table 2). In the tumor core, the percentage of 
cytoplasmic and/or membrane staining for GLUT-
3 was higher in non-metastatic tumors than in 
metastatic tumors (Fig. 1D), but the difference was 
not significant (p=0.499) (Table 2).
With respect to clinical stage, a high percentage 
of cytoplasmic and/or membrane staining for 
GLUT-1 at the deep invasive front and in the tumor 
core was observed in early-stage (stages I/II) and 
advanced tumors (stages III/IV). Statistical analysis 
showed no significant difference between groups 
(Table 2). Cytoplasmic and/or membrane staining 
for GLUT-3 at the deep invasive front was similar 
in early-stage (stages I/II) and advanced tumors 
(stages III/IV) (p=0.892) (Table 2). In the tumor core, 
the percentage of cytoplasmic and/or membrane 
staining for GLUT-3 was higher in early-stage 
tumors (stages I/II) when compared to advanced 
tumors (stages III/IV), but the difference was not 
statistically significant (p=0.786) (Table 2).
Analysis according to histological grade at 
the invasive front showed a predominance of 
cytoplasmic and/or membrane staining for GLUT-1 
at the deep invasive front in both low-grade and 
Table 2. Median percentages of positivity for GLUT-1 and GLUT-3 in the deep 
invasive front and in the tumor core of lower lip squamous cell carcinomas, and 
their differences according to clinicopathologic characteristics
Characteristics
GLUT-1 GLUT-3
Median p Median p
Deep invasive front
 Nodal metastasis
 Present 97.79 0.372 23.98 0.482
 Absent 96.19 26.88
 Clinical staging
 Stages I/ II 95.55 0.341 26.62 0.892
 Stages III/ IV 97.79 26.54
 Histologic grading
 Low grade 96.85 0.447 26.74 0.384
 High grade 97.02 21.64
Tumor core
 Nodal metastasis
 Present 96.43 0.903 19.05 0.499
 Absent 96.30 30.34
 Clinical staging
 Stages I/ II 96.64 0.523 30.34 0.786
 Stages III/ IV 96.27 19.59
 Histologic grading
 Well-differentiated 96.08 0.906 25.02 0.791
 Moderately/ poorly differentiated 96.46 29.86




















high-grade tumors (Fig. 2A). The non-parametric Mann-
Whitney test revealed no statistically significant difference 
between groups (p=0.447) (Table 2). Cytoplasmic and/or 
membrane staining for GLUT-3 at the deep invasive front 
was similar in low-grade and high-grade tumors (Fig. 2B) 
(p=0.384) (Table 2).
Tumors classified as well-differentiated and moderately/
poorly differentiated by the WHO grading system exhibited 
a high percentage of cytoplasmic and/or membrane staining 
for GLUT-1 in the tumor core (Fig. 2C). The non-parametric 
Mann-Whitney test revealed no statistically significant 
difference between groups (p=0.906) (Table 2). The 
percentage of cytoplasmic and/or membrane staining for 
GLUT-3 in the tumor core was similar in well-differentiated 
and moderately/poorly differentiated tumors (Fig. 2D) 
(p=0.791) (Table 2).
The non-parametric Wilcoxon signed rank test revealed 
a significantly higher percentage of GLUT-1-positive cells 
in comparison with GLUT-3-positive cells both in the deep 
invasive front (p<0.001) and in the tumor core (p<0.001) of 
LLSCCs. Spearman’s correlation test revealed a significant 
positive correlation between the percentage of cytoplasmic 
and/or membrane staining for GLUT-1 at the deep invasive 
front and in the tumor core (r=0.679; p<0.001). Similarly, 
there was a positive correlation between the percentage 
of cytoplasmic and/or membrane staining for GLUT-3 at 
the deep invasive front and in the tumor core (r=0.589; 
p<0.001).
Discussion
Malignant neoplastic cells exhibit an altered metabolism 
which is characterized by the increased absorption and 
utilization of glucose (5,7,8). This phenomenon can be 
explained by several mechanisms, including the adaptation 
of cells to the hypoxic tumor microenvironment. Tumor 
hypoxia is caused by factors such as rapid tumor growth, the 
inability of angiogenesis to accompany tumor development, 
disorganized vascular growth resulting in ischemic areas, 
Figure 1. A: High percentage of staining for GLUT-1 in the invasive front of metastatic LLSCC (Advance, 100×). B: Predominantly peripheral staining 
for GLUT-1 in the tumor core of non-metastatic LLSCC (Advance, 200×). C: Low percentage of staining for GLUT-3 in the invasive front of non-
metastatic LLSCC (Advance, 200×). D: Predominantly central staining for GLUT-3 in the tumor core of metastatic LLSCC (Advance, 200×).











and an increased hydrostatic pressure inside the tumor that 
causes microvascular compression (19,20). Therefore, the 
maintenance of tumor cell viability depends in part on the 
ability of these cells to perform anaerobic glycolysis (6).
Hypoxia is an important characteristic of solid tumors 
and advanced head and neck carcinomas and this condition 
is associated with a poor prognosis (11,21). GLUT-1 and 
GLUT-3 mediate glucose uptake by cancer cells, regulating 
energy metabolism, and have been related to the aggressive 
behavior of some tumors (7,9,12,21). Few studies have 
investigated the expression of GLUT-1 and GLUT-3 in OSCC 
(4,10–13,22,23) and, to the authors’ knowledge, there are no 
investigations on the immunoexpression of these glucose 
transporters in LLSCC. Important membrane/cytoplasmic 
immunoexpression of GLUT-1 has been demonstrated 
in OSCCs, particularly at the periphery of tumor islands, 
whereas significantly lower expression was observed in the 
center of the tumor (8,10,11,13–15,22). Similar results were 
obtained in the present study, suggesting that GLUT-1 plays 
an important role in glucose uptake in LLSCCs.
According to Ayala et al. (15), the lack of 
immunoexpression of GLUT-1 in the central areas of tumor 
islands is a characteristic finding in well-differentiated 
OSCCs. On the other hand, poorly differentiated tumors 
exhibit a pattern of GLUT-1 immunoexpression described by 
the authors as antistromal, i.e., enhanced immunostaining 
in central and perinecrotic zones. Similarly, Oliver et al. 
(10) observed strong immunostaining for GLUT-1 in areas 
of necrosis in OSCCs. In the present study, despite the 
identification of strong GLUT-1 immunostaining in areas 
of necrosis, no significant differences in the expression 
of this protein were observed between tumors with 
different histological grades of malignancy (p>0.05). 
These results suggest that the immunoexpression of this 
glucose transporter is not related to the degree of cell 
differentiation in LLSCCs. Supporting this suggestion, Eckert 
et al. (13) and Yamada et al. (23) found no significant 
association between histological grade of malignancy and 
Figure 2. A: Immunoexpression of GLUT-1 in the invasive front of high-grade LLSCC (Advance, 400×). B: Immunoreactivity for GLUT-3 in the invasive 
front of low-grade LLSCC (Advance, 200×). (C) Immunoexpression of GLUT-1 in the tumor core of well-differentiated LLSCC (Advance, 200×). D: 
Immunoreactivity for GLUT-3 in the tumor core of moderately differentiated LLSCC (Advance, 400×).




















GLUT-1 immunoexpression in OSCCs.
In the present study including cases of LLSCC, 
immunostaining for GLUT-3 was much lower than that 
for GLUT-1. In addition, GLUT-3 staining prevailed in 
central areas of tumor nests, islands and sheets. These 
findings suggest that the expression of GLUT-3 represents 
a secondary glucose uptake mechanism in LLSCCs, which 
is only important for central cells in tumor nests, islands 
and sheets. Similarly, Ayala et al. (15) observed GLUT-
3 immunostaining in only 30 (21.1%) of 142 OSCCs 
analyzed, and Zhou et al. (24) found no immunoexpression 
of this glucose transporter in any of 38 head and neck 
carcinomas. On the other hand, Tian et al. (22) observed 
GLUT-3 immunostaining in 16 (84.2%) of 19 OSCC cases 
analyzed. Despite the high percentage of positive cases, 
the authors found no significant association between 
the histological grade of the tumor and expression of 
this glucose transporter. Zhou et al. (24) also observed no 
association between expression of the GLUT-3 gene and the 
degree of cell differentiation in head and neck carcinomas. 
In the present study, GLUT-3 expression did not differ 
significantly between tumors with different histological 
grades of malignancy (p>0.05), suggesting that, as observed 
for GLUT-1, immunoexpression of GLUT-3 is not related to 
the degree of cell differentiation in LLSCCs.
A positive correlation was observed between the 
percentage of GLUT-1 immunoexpression at the invasive 
front and in the center of LLSCCs. Similar results were 
obtained for GLUT-3. Taken together, these findings suggest 
that, in LLSCC, increased glycolytic metabolism is not 
restricted to neoplastic cells at the tumor-host interface, 
a site where several important molecular events occur 
that are intimately related to enhanced cell metabolism, 
including cell proliferation and the secretion of proteolytic 
enzymes (17). This increased cell metabolism at the invasive 
front may contribute to increase hypoxia in central areas 
of LLSCCs. As part of the adaptation process to hypoxic 
conditions, central cells of the tumor increase the expression 
of GLUT-1 and -3 and, consequently, glucose uptake and 
glycolytic metabolism.
Studies have shown an association between the 
overexpression of GLUT-1 in OSCCs and presence of lymph 
node metastasis (10–12), episodes of recurrence (10,14) and 
lower patient survival (4,13–15), suggesting an important 
relationship between the expression of this glucose 
transporter and patient prognosis. However, Ohba et al. (8) 
found no association between the immunoexpression of 
GLUT-1 in OSCCs and clinical stage or lymph node metastasis. 
Roh et al. (11) also observed no significant correlation 
between GLUT-1 immunoexpression and survival of patients 
with tongue carcinoma. In the study of Yamada et al. (23), 
expression of GLUT-1 was not significantly associated with 
tumor size or regional metastasis in patients with OSCCs. In 
the present investigation, GLUT-1 immunoexpression was 
not associated with any of the clinical parameters (regional 
lymph node metastasis and clinical stage), suggesting that 
this protein is not involved in the progression of LLSCCs.
With respect to GLUT-3, Ayala et al. (15) reported an 
association of the expression of this protein with advanced 
clinical stage of OSCC and lower disease-free survival rates. 
In contrast, Zhou et al. (24) showed that the expression 
of the GLUT-3 gene in head and neck carcinomas was 
associated with regional lymph node metastasis, but 
not with clinical stage of the tumor. Tian et al. (22) also 
found no association between GLUT-3 immunoexpression 
and clinical stage in OSCCs. In the present study, GLUT-3 
immunoreactivity was low in LLSCCs. In addition, there 
was no association between the immunoexpression of 
this protein and regional lymph node metastasis or clinical 
stage. These results suggest that GLUT-3 plays only a minor 
role in glucose uptake in LLSCCs and is not involved in the 
progression of these tumors.
Therefore, the present results suggest that increased 
glucose uptake by neoplastic cells is not essential for 
the progression of LLSCC. However, it cannot be ruled 
out the possibility that subsequent events, such as the 
metabolism of glucose, contribute more significantly to 
tumor progression. Within this context, isoenzymes of 
the lactate dehydrogenase family, particularly lactate 
dehydrogenase 5 (LDH5), are important for anaerobic 
glycolysis. These enzymes convert pyruvate into lactate 
(5,25). In a study including 191 cases of OSCC, Grimm et 
al. (25) showed that overexpression of LDH5 was associated 
with the presence of regional lymph node metastasis, 
advanced clinical stage, and lower tumor-specific survival. 
These findings highlight the need for studies investigating 
the effects of alterations in anaerobic glucose metabolism 
on the progression of LLSCCs.
In conclusion, the results of the present study suggest 
an important role of GLUT-1 in glucose uptake in LLSCCs. 
However, this protein does not seem to be involved in the 
progression of these tumors. On the other hand, expression 
of GLUT-3 may represent a secondary glucose uptake 
mechanism in LLSCCs, which is only important for central 
cells in tumor nests, islands and sheets.
Resumo
Este estudo objetivou avaliar a imunoexpressão dos transportadores de 
glicose 1 (GLUT-1) e 3 (GLUT-3) em carcinomas de células escamosas de 
lábio inferior (CCELI) metastáticos e não-metastáticos. Vinte CCELIs com 
metástase nodal regional e 20 CCELI sem metástase foram selecionados. 
Foram analisados a distribuição da imunomarcação e o percentual de 
imunorreatividade para GLUT-1 e GLUT-3 no centro tumoral e no front 
de invasão tumoral. A maioria dos tumores (70%) revelou marcação 
para GLUT-1 em áreas periféricas dos ninhos, lençóis e ilhas de células 
neoplásicas, ao passo que GLUT-3 revelou predomínio de marcação em 











áreas centrais (72.5%). Um alto percentual de células positivas para 
GLUT-1 foi observado no front de invasão e no centro tumoral das lesões 
metastáticas e não-metastáticas (p>0,05). O percentual de células positivas 
para GLUT-1 foi superior ao percentual de células positivas para GLUT-3, 
tanto no front de invasão (p<0,001) quanto no centro tumoral (p<0,001) 
dos CCELIs. Não foram observadas diferenças significativas no percentual 
de células positivas para GLUT-1 e GLUT-3 em relação à mestástase nodal, 
ao estádio clínico ou ao grau histológico de malignidade (p>0,05). Em 
conclusão, os resultados do presente estudo sugerem um importante papel 
para GLUT-1 na absorção de glicose nos CCELIs, embora esta proteína não 
pareça estar envolvida na progressão destes tumores. Por outro lado, a 
expressão de GLUT-3 pode representar um mecanismo secundário para 
a absorção de glicose nos CCELIs.
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